GlassScriptPhysician profile
Joshua Wedding
NPI 1174388441
$3,745.09
in general payments reported to CMS, 2019-2025
21 companies · $2,600 in 2025
The $2,600 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,146 · 2025: $2,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730 · Education: $15.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,729.51 |
| Education | $15.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.75 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $421.13 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $402.87 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $395.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $256.98 | 2024-2025 | |
| Genzyme Corporation | $227.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.27 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Enterra Medical, INC. | $161.76 | 2024 | |
| Ardelyx, INC. | $144.05 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.03 | 2024 | Xifaxan |
| Pfizer INC. | $117.15 | 2024-2025 | |
| Qol Medical, LLC | $104.44 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $82.38 | 2024-2025 | Dupixent |
| Neuraxis, INC. | $47.65 | 2025 | |
| Celltrion USA INC. | $47.31 | 2024-2025 | Vegzelma, Zymfentra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $47.09 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $43.79 | 2024-2025 | |
| Lilly USA, LLC | $30.55 | 2024-2025 | Omvoh |
| Organon LLC | $22.17 | 2025 | Hadlima, Renflexis |
| Tersera Therapeutics LLC | $19.45 | 2025 | Xermelo |
| Aimmune Therapeutics, INC. | $13.82 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Wedding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.